Obesity and psoriasis: the context of new knowledge

Authors: Martin Jozef Péč 1;  Monika Kučeríková 2;  Jakub Jurica 1;  Jakub Benko 1;  Tomáš Bolek 1;  Juraj Sokol 2;  Tatiana Péčová 3;  Matej Samoš 1;  Peter Galajda 1;  Marián Mokáň 1
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin 1;  Onkologické centrum a Klinika hematológie a transfuziológie JLF UK a UNM, Martin 2;  Dermatovenerologická klinika JLF UK a UNM, Martin 3
Published in: Forum Diab 2021; 10(3): 197-200


Psoriasis is a chronic, immunologically mediated, systemic disease that is closely associated with metabolic disorders (insulin resistance, atherogenic dyslipidemia, arterial hypertension, and cardiovascular disease). The most common cardiometabolic disorder associated with psoriasis is metabolic syndrome. Obesity is an independent risk factor for psoriasis and is associated with poorer treatment outcomes due to the high inflammatory activity of visceral adipose tissue and the production of inflammatory mediators involved in the development of psoriasis and individual metabolic disorders. The link between psoriasis and obesity has not been fully elucidated. The article deals with the issue of obesity and psoriasis in the context of new knowledge about adipose tissue in terms of its endocrine function and the release of pro-inflammatory mediators.


obesity – metabolic syndrome – Psoriasis


1. Teklu M, Parel PM, Mehta NN. Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health. Psoriasis (Auckl) 2021; 11: 99–108. Dostupné z DOI: <http://dx.doi.org/10.2147/PTT.S320016>.

2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31(2): 205–212. Dostupné z DOI: <http://dx.doi.org/10.1111/jdv.13854>.

3. Ortonne J, Chimenti S, Luger T et al. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol 2009; 23(12): 1435–1444. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1468–3083.2009.03372.x>.

4. Owczarczyk-Saczonek A, Czerwińska J, Orylska M et al. Evaluation of selected mechanisms of immune tolerance in psoriasis. Postepy Dermatol Alergol 2019; 36(3): 319–328. Dostupné z DOI: <http://dx.doi.org/10.5114/ada.2019.85641>.

5. Alberti KGMM, Zimmet P, Shaw J. [IDF Epidemiology Task Force Consensus Group]. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366(9491): 1059–1062. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67402–8>.

6. Longo M, Zatterale F, Naderi J et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci 2019; 20(9): 2358. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms20092358>.

7. Garshick MS, Ward NL, Krueger JG et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol 2021; 77(13): 1670–1680. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2021.02.009>.

8. Horreau C, Pouplard C, Brenaut E et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27(Suppl 3): 12–29. Dostupné z DOI: <http://dx.doi.org/10.1111/jdv.12163>.

9. Rodríguez-Cerdeira C, Cordeiro-Rodríguez M, CarneroGregorio M et al. Biomarkers of inflammation in obesitypsoriatic patients. Mediators Inflamm 2019; 2019: 7353420. Dostupné z DOI: <http://dx.doi.org/10.1155/2019/7353420>.

10. Owczarczyk-Saczonek A, Placek W. Związki łuszczycy z otyłością i nadwagą. Postępy Hig Med Dosw 2017; 71(1): 761–72. Dostupné z DOI:<http://dx.doi.org/10.5604/01.3001.0010.3854>.

11. Coimbra S, Catarino C, Santos-Silva A. The triad psoriasisobesity-adipokine profile. J Eur Acad Dermatol Venereol 2016; 30(11): 1876–1885. Dostupné z DOI: <http://dx.doi.org/10.1111/jdv.13701>.

12. Naldi L, Addis A, Chimenti S et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Dermatology 2008; 217(4): 365–373. Dostupné z DOI: <http://dx.doi.org/10.1159/000156599>.

13. Han JH, Lee JH, Han KD et al. Increased risk of psoriasis in subjects with abdominal obesity: a nationwide populationbased study. J Dermatol 2019; 46(8): 695–701. Dostupné z DOI: <http://dx.doi.org/10.1111/1346–8138.14939>.

14. Boehncke WH, Boehncke S, Tobin AM et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20(4): 303–307. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600–0625.2011.01261.x>.

15. Jin Y, Zhang F, Yang S et al. Combined effects of HLA-Cw6, body mass index and waist–hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci 2008; 52(2): 123–129. Dostupné z DOI:<http://dx.doi.org/10.1016/j.jdermsci.2008.04.016>.

16. Shipman AR, Millington GWM. Obesity and the skin. Br J Dermatol 2011; 165(4): 743–750. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2133.2011.10393.x>.

17. Vega-Robledo GB, Oliva-Rico D, Rico-Rosillo G. Adipose tissue: function, adipokines, and alterations related with psoriasis. Sci J Clin Res Dermatol 2017; 2(2): 36–42. Dostupné z WWW: <https://www.scireslit.com/Dermatology/SJCRD-ID20.php>.

18. Owczarczyk-Saczonek A, Purzycka-Bohdan D, Nedoszytko B et al. Pathogenesis of psoriasis in the “omic” era. Part III. Metabolic disorders,, metabolomics, nutrigenomics in psoriasis. Postepy Dermatol Alergol 2020; 37(4): 452–467. Dostupné z DOI: <http://dx.doi.org/10.5114/ada.2020.98284>.

19. Raposo I, Torres T. Psoriasis strikes back! Epicardial adipose tissue: another contributor to the higher cardiovascular risk in psoriasis. Rev, Port Cardiol 2015; 34(10): 613–616. Dostupné z DOI: <http://dx.doi.org/10.1016/j.repc.2015.04.007>.

20. Marseglia L, Manti S, D’Angelo G et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 2014; 16(1): 378–400. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms16010378>.

21. Barrea L, Nappi F, Di Somma C et al. Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. Int J Environ Res Public Health 2016; 13(5): 743. Dostupné z DOI: <http://dx.doi.org/10.3390/ijerph13070743>.

22. Davidovici BB, Sattar N, Jörg PC et al. Psoriasis and systemic inflammatory disease: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130(7): 1785–1796. Dostupnéz DOI: <http://dx.doi.org/10.1038/jid.2010.103>.

23. Ouchi N, Parker JL, Lugus JJ et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11(2): 85–97. Dostupné z DOI: <http://dx.doi.org/10.1038/nri2921>.

24. Zhu KJ, Zhang C, Li M et al. Leptin levels in patients with psoriasis: A meta-analysis. Clin Exp Dermatol 2013; 38(5): 478–483. Dostupné z DOI: <http://dx.doi.org/10.1111/ced.12171>.

25. Takahashi H, Tsuji H, Honma M et al. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res 2013; 305(2): 113–116. Dostupné z DOI: <http://dx.doi.org/10.1007/s00403–012–1310–9>.

26. Gisondi P, Lora V, Bonauguri C et al. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 2013; 168(4): 749–755. Dostupné z DOI: <http://dx.doi.org/10.1111/bjd.12118>.

27. Roszkiewicz M, Dopytalska K, Szymańska E et al. Environmental risk factors and epigenetic alternations in psoriasis. Ann Agric Environ Med 2020; 27(3): 335–342. Dostupné z DOI: <http://dx.doi.org/10.26444/aaem/112107>.

28. Phan C, Touvier M, Kesse-Guyot E et al. Association between mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Santé cohort. JAMA Dermatol 2018; 154(9): 1017–1024. Dostupné z DOI: <http://dx.doi.org/10.1001/jamadermatol.2018.2127>.

29. Millsop JW, Bhatia BK, Debbaneh M et al. Diet and Psoriasis: Part 3. Role of Nutritional Supplements. J Am Acad Dermatol 2014; 71(3): 561– 569. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaad.2014.03.016>.

30. Bhatia BK, Millsop JW, Debbaneh M et al. Diet and Psoriasis: Part 2. Celiac Disease and Role of a Gluten-Free Diet. J Am Acad Dermatol 2014; 71(2): 350–358. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaad.2014.03.017>.

31. Salas-Salvadó J, Guasch-Ferré M, Lee CH et al. Protective effects of the mediterranean diet on type 2 diabetes and metabolic syndrome. J Nutr. 2016; 146(4): S920–S927. Dostupné z DOI: <http://dx.doi.org/10.3945/jn.115.218487>.

32. Stehlikova Z, Kostovcikova K, Kverka M et al. Crucial role of microbiota in experimental psoriasis revealed by a gnotobiotic mouse model. Front Microbiol 2019; 10: 236. Dostupné z DOI: <http://dx.doi.org/10.3389/fmicb.2019.00236>.

33. Woo V, Alenghat T. Host-microbiota interactions: epigenomic regulation. Curr Opin Immunol. 2017; 44: 52–60. Dostupné z DOI: <http://dx.doi.org/10.1016/j.coi.2016.12.001>.

34. Speeckaert R, Lambert J, Grine L et al. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol 2016; 175(5): 892–901. Dostupné z DOI: <http://dx.doi.org/10.1111/bjd.14703>.

35. Zákostelská Z, Málková J, Klimešová K et al. Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response. PLoS One 2016; 11(7): e0159539. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0159539>.

36. Forbes JD, Van Domselaar G, Bernstein CN. The Gut Microbiota in Immune-Mediated Inflammatory Diseases. Front Microbiol 2016; 7: 1081. Dostupné z DOI: <http://dx.doi.org/10.3389/fmicb.2016.01081>.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account